Liberalization and Protection: Antidumping Duties in the Indian Pharmaceutical Industry

17 Pages Posted: 30 May 2008 Last revised: 7 Aug 2008

See all articles by Nisha Malhotra

Nisha Malhotra

University of British Columbia

Shavin Malhotra

Carleton University - Eric Sprott School of Business

Date Written: 2007

Abstract

In this paper we investigate whether antidumping (AD) actions in the Indian pharmaceutical industry have restricted trade from countries that were named to be dumping, or whether trade was diverted to other countries not named in these petitions. We found no evidence of trade diversion. It is a bad news for consumers, as a restrictive trade policy translates into higher prices for the importing good. In a country where only 30% of the population can afford access to modern drugs, the trade effect due to AD laws must be carefully evaluated.

Keywords: Antidumping, India, Pharmaceutical Industry, Trade

JEL Classification: J13

Suggested Citation

Malhotra, Nisha and Malhotra, Shavin, Liberalization and Protection: Antidumping Duties in the Indian Pharmaceutical Industry (2007). Available at SSRN: https://ssrn.com/abstract=1139226 or http://dx.doi.org/10.2139/ssrn.1139226

Nisha Malhotra (Contact Author)

University of British Columbia ( email )

997-1873 East Mall
Vancouver, BC V6T1Z1
Canada

HOME PAGE: http://www.econ.ubc.ca/nmalhotra/homepage.htm

Shavin Malhotra

Carleton University - Eric Sprott School of Business ( email )

1125 Colonel By Drive
Ottawa, Ontario K1S SB6
Canada

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
190
Abstract Views
1,143
rank
180,080
PlumX Metrics